NCT04733651

Study to Investigate the Clinical Efficacy of Isoquercetin in Patients With COVID-19

A Randomized, Open-labelled and Controlled Clinical Trial to Investigate the Clinical Efficacy of Isoquercetin in the Treatment of Mild-to-moderate Hospitalised COVID-19 Patients

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 250 (estimated)
• Sponsor: Nepal Health Research Council · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the clinical efficacy of Isoquercetin in preventing disease progression and symptoms improvement in mild-to-moderate hospitalised COVID-19 patients.

Detailed description

This is an open-labelled, randomized and multi-centre clinical trial in subjects with RT-PCR confirmed SARS-CoV-2 infection with mild-to-moderate symptoms, and who are currently admitted to the hospital for diagnosis of COVID-19. The study has two arms: hospital standard COVID-19 care (Control group) and hospital standard COVID-19 care + Isoquercetin (Isoquercetin group). The recruited subjects will be placed into either group by an electronic randomization process. Patients in the Isoquercetin group will receive a daily dose of 1000 mg Isoquercetin as 4 x 250 mg Isoquercetin capsules as add-on therapy in addition to the hospital standard COVID-19 care. The Isoquercetin treatment will continue for 28 days.

Conditions

• Covid19

Interventions

Type	Name	Description
DRUG	Hospital standard of care for COVID-19	Standard care for COVID-19 as per the hospital guidelines
DRUG	Isoquercetin	Daily 1000 mg Isoquercetin as 4 capsules

Timeline

• Start date: 2021-02-20
• Primary completion: 2021-05-20
• Completion: 2021-08-15
• First posted: 2021-02-02
• Last updated: 2021-02-05